SK14052003A3 - Použitie derivátov adenozínu na prípravu liečiva na liečenie syndrómu inzulínovej rezistencie a diabetu - Google Patents

Použitie derivátov adenozínu na prípravu liečiva na liečenie syndrómu inzulínovej rezistencie a diabetu Download PDF

Info

Publication number
SK14052003A3
SK14052003A3 SK1405-2003A SK14052003A SK14052003A3 SK 14052003 A3 SK14052003 A3 SK 14052003A3 SK 14052003 A SK14052003 A SK 14052003A SK 14052003 A3 SK14052003 A3 SK 14052003A3
Authority
SK
Slovakia
Prior art keywords
ylamino
purin
diol
pyrrolidin
hydroxymethyl
Prior art date
Application number
SK1405-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Andreas Herling
Gerhard J�Hne
Martin P. Maguire
Alfred P. Spada
Michael R. Myers
Yong Mi Choi-Sledeski
Heinz W. Pauls
William R. Ewing
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of SK14052003A3 publication Critical patent/SK14052003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK1405-2003A 2001-05-14 2002-05-14 Použitie derivátov adenozínu na prípravu liečiva na liečenie syndrómu inzulínovej rezistencie a diabetu SK14052003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
SK14052003A3 true SK14052003A3 (sk) 2004-07-07

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1405-2003A SK14052003A3 (sk) 2001-05-14 2002-05-14 Použitie derivátov adenozínu na prípravu liečiva na liečenie syndrómu inzulínovej rezistencie a diabetu

Country Status (23)

Country Link
US (1) US20030176390A1 (cs)
EP (2) EP1258247A1 (cs)
JP (1) JP2004533448A (cs)
KR (1) KR20040002962A (cs)
CN (1) CN1518450A (cs)
BG (1) BG108356A (cs)
BR (1) BR0209650A (cs)
CA (1) CA2447408A1 (cs)
CO (1) CO5540288A2 (cs)
CZ (1) CZ20033079A3 (cs)
EA (1) EA007253B1 (cs)
EE (1) EE200300551A (cs)
HR (1) HRP20030928A2 (cs)
HU (1) HUP0400464A3 (cs)
IL (1) IL158794A0 (cs)
MX (1) MXPA03010336A (cs)
NO (1) NO20035056D0 (cs)
NZ (1) NZ529390A (cs)
PL (1) PL364573A1 (cs)
SK (1) SK14052003A3 (cs)
WO (1) WO2002092093A1 (cs)
YU (1) YU90203A (cs)
ZA (1) ZA200308777B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
IL158794A0 (en) 2004-05-12
JP2004533448A (ja) 2004-11-04
CN1518450A (zh) 2004-08-04
WO2002092093A1 (en) 2002-11-21
HUP0400464A2 (hu) 2004-07-28
HRP20030928A2 (en) 2005-10-31
EA200301231A1 (ru) 2004-04-29
BG108356A (bg) 2004-12-30
NO20035056D0 (no) 2003-11-13
PL364573A1 (en) 2004-12-13
EP1258247A1 (en) 2002-11-20
YU90203A (sh) 2006-08-17
BR0209650A (pt) 2004-07-13
CO5540288A2 (es) 2005-07-29
US20030176390A1 (en) 2003-09-18
KR20040002962A (ko) 2004-01-07
CZ20033079A3 (cs) 2004-08-18
ZA200308777B (en) 2006-04-26
CA2447408A1 (en) 2002-11-21
EP1404338A1 (en) 2004-04-07
HUP0400464A3 (en) 2007-03-28
NZ529390A (en) 2006-06-30
MXPA03010336A (es) 2004-03-16
EA007253B1 (ru) 2006-08-25
EE200300551A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
EP4271672B1 (en) Carboxy-benzimidazole glp-1r modulating compounds
AP903A (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties.
JP4129176B2 (ja) ２−アミノカルボニル−９ｈ−プリン誘導体類
JP2025098031A (ja) Ｔｙｋ２阻害剤およびその使用方法
CN101056879B (zh) 作为a3和a1腺苷受体激动剂的嘌呤衍生物
US6559313B2 (en) Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties
CN109906083B (zh) 含有腺苷衍生物的药物组合物
CZ20033079A3 (cs) Léčiva s obsahem derivátů adenosinu k léčení syndromu insulinové rezistence a diabetu
JP2954971B2 (ja) 選択的アデノシン受容体剤
IL97656A (en) 1,3-dipropyl-8-aralkyl-xanthine derivatives process for their preparation and pharmaceutical compositions comprising them
US6306847B1 (en) Condensed purine derivatives
AU2002342317A1 (en) Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
JPWO1998015555A1 (ja) 縮合プリン誘導体
HK1129117A (en) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure